GlaxoSmithKline and partner Vir Biotechnology Inc. have teamed up with Indianapolis-based Eli Lilly and Co. to test a combination of their COVID-19 antibody treatments to see whether they can better combat the virus and its variants together.
Merus N.V. specializes is so-called CD3 engaging T-cell therapies, a growing area of cancer research, based on immunotherapy, or using the immune system’s T cells to find and shrink tumors
The Indianapolis-based drugmaker said people from minority communities are frequently “unseen” by the U.S. health care system.
Several other Indiana companies also say they are suspending contributions to all candidates or are taking a close look at the matter.
So far this month, drugmakers have hiked prices on 636 drugs, according to research by GoodRx, which tracks prescription drug prices and offer a mobile app to help consumers find the lowest prices on hundreds of drugs.
The experimental drug, donanemab, could be a huge breakthrough for Lilly, which has spent billions of dollars over 30 years researching treatments for Alzheimer’s disease, only to see them fall short in clinical trials.
For a highly touted drug meant to keep throngs of people out of hospitals during a pandemic, Eli Lilly and Co.’s wonder treatment bamlanivimab sure has been slow to catch on.
Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from the drugs made by Eli Lilly and Co. and Regeneron Pharmaceuticals.
Lilly stock climbed Tuesday after the drugmaker laid out a better-than-expected revenue forecast and plans to buy a young company developing a potential Parkinson’s disease treatment.
Eli Lilly and Co. on Tuesday announced that it is buying New York-based Prevail Therapeutics Inc., an emerging player in the sizzling-hot area of gene therapies, which targets Parkinson’s disease and other brain-related maladies.
Doctors are reporting that a two-drug treatment involving a medication from Indianapolis-based Eli Lilly and Co. is especially helpful for COVID-19 patients who need extra oxygen.
The medication will be provided by the U.S. government, which paid Indianapolis-based Lilly $375 million for an initial two-month supply of 300,000 doses as part of the Operation Warp Speed program.
Lilly said it will enroll up to 500,000 people in its latest study, with at least 5,000 people expected to receive bamlanivimab therapy. The drugmaker is partnering with health insurer UnitedHealth Group to see if the drug will help high-risk people.
During IBJ’s Engage Indiana 2020 virtual event Thursday morning, Eli Lilly & Co. CEO Dave Ricks said he always believed enhancing diversity and inclusion was important, but this year showed him how serious a problem racial injustice is and fueled his motivation to do more to address it.
CVS has developed a program to provide the treatments in their homes, but it won’t be available—at least initially—in Indianapolis.
In a separate development, the FDA on Thursday gave emergency authorization to use of another anti-inflammatory drug sold by Eli Lilly, baricitinib, to be used with remdesivir.
The Indianapolis drugmaker said Thursday evening it was awarded an emergency use authorization for its drug baricitinib to be used in combination with Gilead Sciences’ antiviral drug remdesivir in severely ill, hospitalized patients with COVID-19.
Because of the initial limited supply, the number of doses each state receives will be determined by the number of confirmed cases and hospitalizations in a given week, federal officials said.
The initial scarcity of the drug and the logistical complexities of administering it could mute its immediate impact on the pandemic and raise questions about whether it is being distributed to people in the greatest need.
The Food and Drug Administration on Monday cleared the experimental drug from Indianapolis-based Eli Lilly and Co. for people 12 and older with mild or moderate COVID-19 not requiring hospitalization. It’s a one-time treatment given through an IV.
